Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01589094 | Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT00794950 | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma(Sutent) | completed | Phase 2 | 43 | University of MichiganOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02843607 | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02351739 | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer(KEYNOTE143) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01282463 | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | completed | Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT03507166 | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01373294 | Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00569946 | Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT00853021 | Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney | completed | Phase 2 | 26 | Jorge A. Garcia, MDOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01191892 | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | completed | Phase 2 | 82 | Cardiff UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT00526656 | Sunitinib in Treating Patients With Locally Advanced Bladder Cancer | completed | Phase 2 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02109328 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | completed | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT01731158 | Sequential Therapy in Metastatic Renal Cell Carinoma(BERAT) | completed | Phase 2 | 22 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT01743469 | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers | completed | Phase 2 | 201 | IpsenINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT01688973 | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01762150 | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | completed | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 361 | National Cancer Institute (NCI)NIH | 2 | Nov 14, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01158222 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | completed | Phase 2 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01158521 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT00578526 | SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial(SPRUCE) | completed | Phase 2 | 64 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00310011 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 71 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00112671 | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00085436 | DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC | completed | Phase 2 | 18 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00729053 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | completed | Phase 2 | 92 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 12, 2018 | clinicaltrials |
| NCT00963404 | Image-Guided Tumorboost of Bladder Cancer | completed | Phase 1 / Phase 2 | 19 | University of AarhusOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01829841 | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer | completed | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 3, 2018 | clinicaltrials |
| NCT00529802 | Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer | completed | Phase 2 | 60 | University of ChicagoOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01361113 | Neoadjuvant Pazopanib in Renal Cell Carcinoma | completed | Phase 2 | 21 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00923130 | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | completed | Phase 1 / Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00448721 | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer | completed | Phase 2 | 24 | AEterna ZentarisINDUSTRY | 1 | Mar 1, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2019source: clinicaltrials